NASDAQ:VXRT - Vaxart Stock Price, Forecast & News

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Vaxart shares reverse split on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

Vaxart Inc (NASDAQ:VXRT) released its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.36) by $0.04. The biotechnology company had revenue of $0.45 million for the quarter, compared to the consensus estimate of $0.44 million. Vaxart had a negative return on equity of 115.71% and a negative net margin of 222.20%. View Vaxart's Earnings History.

Vaxart is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Vaxart.

2 analysts have issued 12-month target prices for Vaxart's shares. Their forecasts range from $2.00 to $6.00. On average, they anticipate Vaxart's stock price to reach $4.00 in the next year. This suggests a possible upside of 267.0% from the stock's current price. View Analyst Price Targets for Vaxart.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vaxart.

News coverage about VXRT stock has been trending somewhat positive this week, according to InfoTrie. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vaxart earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Vaxart.

Some companies that are related to Vaxart include Verona Pharma (TARA), CASI Pharmaceuticals (CASI), Jounce Therapeutics (JNCE), Windtree Therapeutics (WINT), Fennec Pharmaceuticals (FENC), Dyadic International (DYAI), Solid Biosciences (SLDB), Brainstorm Cell Therapeutics (BCLI), X4 Pharmaceuticals (XFOR), Erytech Pharma (ERYP), Gamida Cell (GMDA), Axcella Health (AXLA), Surface Oncology (SURF), Cidara Therapeutics (CDTX) and Applied Genetic Technologies (AGTC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Conatus Pharmaceuticals (CNAT), Agile Therapeutics (AGRX), vTv Therapeutics (VTVT), Nabriva Therapeutics (NBRV), VBI Vaccines (VBIV), Aduro BioTech (ADRO), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL), TrovaGene (TROV) and Armata Pharmaceuticals (ARMP).

Vaxart's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.87%). Company insiders that own Vaxart stock include Armistice Capital Master Fund, John P Richard, Michael J Finney, Sean Tucker and Wouter Latour. View Institutional Ownership Trends for Vaxart.

VXRT stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Vaxart stock in the last two years include Armistice Capital Master Fund, John P Richard, Michael J Finney, Sean Tucker and Wouter Latour. View Insider Buying and Selling for Vaxart.

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VXRT stock can currently be purchased for approximately $1.09.

Vaxart has a market capitalization of $52.02 million and generates $4.16 million in revenue each year. The biotechnology company earns $-18,000,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis. Vaxart employs 34 workers across the globe.View Additional Information About Vaxart.

The official website for Vaxart is http://www.vaxart.com/.

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected]